Your session is about to expire
← Back to Search
Intravenous Ketamine for Major Depressive Disorder
Study Summary
This trial will test whether mindfulness training enhances the effects of ketamine for depression.
- Major Depressive Disorder
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have been diagnosed with bipolar disorder, psychosis, or autism spectrum disorder at any point in your life.You have had a bad reaction or allergy to ketamine in the past.You are taking certain medications that affect specific receptors in the brain, such as glutamate or opioid receptors. However, one medication called lamotrigine is allowed because it does not affect the safety or effectiveness of the study drug.You are currently taking medications like St. John's Wort, theophylline, tramadol, or metrizamide.You have a score of 14 or higher on the Hamilton Depression Rating Scale (modified Ham-D).You have been practicing mindfulness meditation for more than one hour per week, on average, for at least the past six months.You are between the ages of 18 and 65 years.You currently have a serious problem with using drugs or alcohol.You are currently experiencing severe mental health issues that require immediate treatment.You have undergone electroconvulsive therapy (ECT) within the last 2 months before the screening.You have had one or more seizures without a clear cause that has been resolved.
- Group 1: Intravenous Ketamine + Academic Exercises
- Group 2: Intravenous Ketamine + Mindfulness Exercises
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are currently enrolled in this trial?
"Affirmative. According to clinicaltrials.gov, this experiment commenced on February 1st 2022 and is still actively recruiting participants as of March 4th 2022. The research team are hoping to acquire 60 people from a single medical centre for the trial's duration."
Is this study currently accepting new participants?
"Affirmative. According to details listed on clinicaltrials.gov, this investigation was uploaded on February 1st 2022 and is presently recruiting participants. The team needs 60 individuals from one medical facility to take part in the study."
What results is this research endeavor seeking to uncover?
"The primary aim of this clinical test is to measure Montgomery-Asberg Depression Rating Scale over the course of 80 minutes post-infusion. Additionally, it will also assess Quick Inventory of Depressive Symptoms (with higher scores indicating a worse outcome), Hood Mysticism Scale (higher scores implying greater mystical experience) and Mindful Attention Awareness Scale (a scale ranging from 1-6 with higher numbers demonstrating increased mindfulness)."
Who is best suited to join this experiment?
"In order to qualify for this medical trial, applicants must suffer from depression and should be between 18-65 years old. Around 60 people are being admitted into the study."
Does this medical trial allow people younger than fifty years old to participate?
"This medical experiment is open to participants above the age of majority and below 65 years old."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger